R&D News | pharmaphorum

News

Roche builds gene therapy portfolio with SpliceBio deal

Roche’s gene therapy unit Spark has added to its pipeline in inherited retinal diseases (IRDs) with a $216 million alliance with Spanish biotech SpliceBio.

News

Owkin signs up another pharma partner for its AI platform

France’s Servier has become the latest pharma group to tap into an artificial intelligence platform for drug discovery, development, and diagnostics developed by Franco-US

News

Novo Nordisk cuts $1.3bn deal for KBP blood pressure drug

Novo Nordisk has agreed a $1.3 billion deal with Singapore’s KBP Biosciences to buy ocedurenone, a drug for uncontrolled hypertension that ties in with its ongoing efforts

News

AbbVie’s Skyrizi bests Stelara in Crohn’s contest

AbbVie has built the case for its IL-23 inhibitor Skyrizi as a treatment for Crohn’s disease, saying its drug was more effective than Johnson & Johnson’s widely-used S

News

MSD gives warning to UK ahead of $1.3bn facility work

In 2017, MSD made the decision to open a $1.32 billion, 220,000 sq ft research facility in the heart of London’s ‘knowledge quarter’ around King’s Cross.

News

Santhera closes on first approval for DMD drug vamorolone

Swiss biotech Santhera is on the brink of its first regulatory approval for Duchenne muscular dystrophy treatment vamorolone, after getting a positive opinion on the drug

Roche builds gene therapy portfolio with SpliceBio deal

Owkin signs up another pharma partner for its AI platform

Novo Nordisk cuts $1.3bn deal for KBP blood pressure drug

AbbVie’s Skyrizi bests Stelara in Crohn’s contest

MSD gives warning to UK ahead of $1.3bn facility work

Santhera closes on first approval for DMD drug vamorolone

Novo Nordisk rises as Hims & Hers backs down on oral GLP-1

How to meet your physicians where they are online

News

Editor's Picks